JP2011501951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501951A5 JP2011501951A5 JP2010531076A JP2010531076A JP2011501951A5 JP 2011501951 A5 JP2011501951 A5 JP 2011501951A5 JP 2010531076 A JP2010531076 A JP 2010531076A JP 2010531076 A JP2010531076 A JP 2010531076A JP 2011501951 A5 JP2011501951 A5 JP 2011501951A5
- Authority
- JP
- Japan
- Prior art keywords
- scaffold
- chain
- seq
- loop
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000001014 amino acid Nutrition 0.000 claims 15
- 229940024606 amino acid Drugs 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000019040 Nuclear Antigens Human genes 0.000 claims 1
- 108010051791 Nuclear Antigens Proteins 0.000 claims 1
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98420907P | 2007-10-31 | 2007-10-31 | |
| PCT/US2008/012398 WO2009058379A2 (en) | 2007-10-31 | 2008-10-31 | Protein scaffolds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014243591A Division JP6034846B2 (ja) | 2007-10-31 | 2014-12-02 | タンパク質足場 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501951A JP2011501951A (ja) | 2011-01-20 |
| JP2011501951A5 true JP2011501951A5 (OSRAM) | 2011-12-22 |
Family
ID=40591700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531076A Pending JP2011501951A (ja) | 2007-10-31 | 2008-10-31 | タンパク質足場 |
| JP2014243591A Active JP6034846B2 (ja) | 2007-10-31 | 2014-12-02 | タンパク質足場 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014243591A Active JP6034846B2 (ja) | 2007-10-31 | 2014-12-02 | タンパク質足場 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8633297B2 (OSRAM) |
| EP (1) | EP2215246B1 (OSRAM) |
| JP (2) | JP2011501951A (OSRAM) |
| KR (1) | KR101686247B1 (OSRAM) |
| CN (1) | CN101932720A (OSRAM) |
| AU (1) | AU2008319298B2 (OSRAM) |
| BR (1) | BRPI0818810A2 (OSRAM) |
| CA (1) | CA2704229C (OSRAM) |
| ES (1) | ES2533874T3 (OSRAM) |
| MX (1) | MX2010004374A (OSRAM) |
| RU (1) | RU2010121967A (OSRAM) |
| WO (1) | WO2009058379A2 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| CA2670471A1 (en) | 2006-11-22 | 2008-06-05 | Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
| CN102007145A (zh) | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| MX2010011957A (es) | 2008-05-02 | 2011-03-04 | Novartis Ag Star | Moleculas de union basadas en fibronectina mejoradas y usos de las mismas. |
| EP2799448A1 (en) | 2008-05-22 | 2014-11-05 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| CN102307896B (zh) | 2008-10-31 | 2016-10-12 | 森托科尔奥索生物科技公司 | 基于iii型纤连蛋白结构域的支架组合物、方法及用途 |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| ES2860453T3 (es) * | 2009-10-30 | 2021-10-05 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| AU2011240620A1 (en) * | 2010-04-13 | 2012-10-18 | Medimmune, Llc | Fibronectin type III domain-based multimeric scaffolds |
| HUE029622T2 (en) * | 2010-04-30 | 2017-03-28 | Janssen Biotech Inc | Stabilized fibronectin domain compositions, methods and uses |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| CA2827007A1 (en) * | 2011-02-11 | 2012-08-16 | Research Corporation Technologies, Inc. | Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds |
| ES2608835T3 (es) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| EP2709669A1 (en) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| EP2761066B1 (en) | 2011-09-27 | 2018-12-05 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| SG10201707813YA (en) * | 2011-10-11 | 2017-11-29 | Medimmune Llc | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| PL2780370T3 (pl) * | 2011-11-16 | 2020-01-31 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjenta |
| ES2707878T3 (es) * | 2011-11-16 | 2019-04-05 | Adrenomed Ag | Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para regular el equilibrio de líquidos en un paciente que presenta una enfermedad crónica o aguda |
| ES2729710T3 (es) * | 2011-11-16 | 2019-11-05 | Adrenomed Ag | Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para la prevención o la reducción de una disfunción orgánica o una insuficiencia orgánica en un paciente que presenta una enfermedad crónica o aguda o una afección aguda |
| LT3835310T (lt) | 2012-09-13 | 2024-04-25 | Bristol-Myers Squibb Company | Fibronektino pagrindo karkaso domeno baltymai, kurie rišasi prie miostatino |
| EP2951206A2 (en) | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| ES2689372T3 (es) | 2013-02-06 | 2018-11-13 | Bristol-Myers Squibb Company | Proteínas de dominio de fibronectina tipo III con solubilidad mejorada |
| US10183967B2 (en) | 2013-02-12 | 2019-01-22 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| ES2870802T3 (es) | 2013-02-12 | 2021-10-27 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| ES2644022T3 (es) | 2013-03-14 | 2017-11-27 | Bristol-Myers Squibb Company | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| WO2015143199A1 (en) | 2014-03-20 | 2015-09-24 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
| EP3647322B1 (en) | 2014-03-20 | 2021-10-20 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
| US10562946B2 (en) | 2014-06-20 | 2020-02-18 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
| RU2715905C2 (ru) | 2014-10-01 | 2020-03-04 | МЕДИММЬЮН, ЭлЭлСи | Способ конъюгации полипептида |
| US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
| CN107207379B (zh) | 2014-11-25 | 2021-08-10 | 百时美施贵宝公司 | 用于生物制品的18f-放射性标记的方法和组合物 |
| CA2977675A1 (en) | 2015-03-12 | 2016-09-15 | Medimmune, Llc | Method of purifying albumin-fusion proteins |
| EP3708580B1 (en) | 2015-09-23 | 2023-11-01 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| HK1254837A1 (zh) * | 2015-10-30 | 2019-07-26 | Janssen Vaccines & Prevention B.V. | D-蛋白质配体的基於结构的设计 |
| CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| TW201825118A (zh) * | 2016-11-30 | 2018-07-16 | 美商艾堤爾製藥公司 | 抗-hrs抗體及用於治療癌症之組合療法 |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| WO2018202870A1 (en) * | 2017-05-04 | 2018-11-08 | Follicum Ab | Peptides for treatment of diabetes |
| AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| WO2019165017A1 (en) * | 2018-02-23 | 2019-08-29 | The University Of Chicago | Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies |
| CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
| JP7772687B2 (ja) | 2019-07-15 | 2025-11-18 | メディミューン リミテッド | タンパク質二量体化の三分子システム及び使用方法 |
| EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | ARO Biotherapeutics Company | FIBRONECTIN TYPE III DOMAINS BINDING TO CD137 |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN116568341A (zh) | 2020-02-28 | 2023-08-08 | 百时美施贵宝公司 | 基于纤连蛋白的放射性标记的支架和抗体及其治疗诊断用途 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| US11566346B2 (en) | 2020-06-25 | 2023-01-31 | Philip David Rodley | Protein scaffold |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2024261323A1 (en) | 2023-06-23 | 2024-12-26 | Astrazeneca Ab | Molecular switches |
| WO2025125630A1 (en) | 2023-12-15 | 2025-06-19 | Medimmune Limited | Method for bioprotac design |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734033A (en) | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US5618709A (en) | 1994-01-14 | 1997-04-08 | University Of Pennsylvania | Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein |
| US6482410B1 (en) * | 1994-09-16 | 2002-11-19 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same |
| US5998596A (en) | 1995-04-04 | 1999-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of protein kinase activity by aptameric action of oligonucleotides |
| AU5779696A (en) | 1995-06-01 | 1996-12-18 | Kishimoto, Tadamitsu | Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1) |
| GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
| US6127366A (en) | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EE03484B1 (et) | 1995-12-08 | 2001-08-15 | Janssen Pharmaceutica N.V. | Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine |
| WO1997027852A1 (en) | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000504017A (ja) | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5891889A (en) | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
| CA2259222A1 (en) | 1996-06-27 | 1997-12-31 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| US6040305A (en) | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US5945429A (en) | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6030982A (en) | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
| US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
| US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6093737A (en) | 1996-12-30 | 2000-07-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6013662A (en) | 1996-12-30 | 2000-01-11 | Rhone-Poulenc Rorer S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| ZA981080B (en) | 1997-02-11 | 1998-08-12 | Warner Lambert Co | Bicyclic inhibitors of protein farnesyl transferase |
| TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6239140B1 (en) | 1997-06-17 | 2001-05-29 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6211193B1 (en) | 1997-06-17 | 2001-04-03 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6228865B1 (en) | 1997-06-17 | 2001-05-08 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6051582A (en) | 1997-06-17 | 2000-04-18 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6159984A (en) | 1997-06-17 | 2000-12-12 | Schering Corporation | Farnesyl protein transferase inhibitors |
| US6225322B1 (en) | 1997-06-17 | 2001-05-01 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6103723A (en) | 1997-10-17 | 2000-08-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DE69801590T2 (de) | 1997-10-22 | 2002-07-11 | Astrazeneca Ab, Soedertaelje | Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren |
| US6124465A (en) | 1997-11-25 | 2000-09-26 | Rhone-Poulenc S.A. | Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments |
| EP1045846B1 (en) | 1997-11-28 | 2003-05-02 | Lg Chemical Limited | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
| US6054466A (en) | 1997-12-04 | 2000-04-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2002513031A (ja) | 1998-04-27 | 2002-05-08 | ワーナー−ランバート・カンパニー | ファルネシルトランスフェラーゼ阻害剤としての機能化されたアルキルおよびアルケニル側鎖を有するグリシンアミド誘導体 |
| US6160089A (en) * | 1998-07-08 | 2000-12-12 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
| PT1137941E (pt) | 1998-12-10 | 2009-10-15 | Brystol Myers Squibb Company | Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) * | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6362188B1 (en) | 1998-12-18 | 2002-03-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
| US6372747B1 (en) | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
| FR2787327B1 (fr) | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| US6143766A (en) | 1999-04-16 | 2000-11-07 | Warner-Lambert Company | Benzopyranone and quinolone inhibitors of ras farnesyl transferase |
| AU2001277867B2 (en) * | 2000-07-11 | 2006-12-07 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| EP3023501A1 (en) * | 2002-03-29 | 2016-05-25 | Danisco US Inc. | Enhanced protein expression in bacillus |
| AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
| US20060141561A1 (en) * | 2002-06-24 | 2006-06-29 | Kelley Robert F | Apo-2 ligand/trail variants and uses thereof |
| US7175895B2 (en) * | 2003-11-19 | 2007-02-13 | Kimberly-Clark Worldwide, Inc. | Glove with medicated porous beads |
| KR20060129246A (ko) * | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| KR100852415B1 (ko) * | 2004-07-13 | 2008-08-18 | 재단법인서울대학교산학협력재단 | 인간 테나신―ｃ 유래의 신규한 헤파린-결합부위를포함하는 폴리펩타이드 및 그의 유도체 |
| GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
| JP4959226B2 (ja) | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| CA2670471A1 (en) | 2006-11-22 | 2008-06-05 | Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
| AU2008345424A1 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| MX2010011957A (es) | 2008-05-02 | 2011-03-04 | Novartis Ag Star | Moleculas de union basadas en fibronectina mejoradas y usos de las mismas. |
| EP2799448A1 (en) | 2008-05-22 | 2014-11-05 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| CN102307896B (zh) | 2008-10-31 | 2016-10-12 | 森托科尔奥索生物科技公司 | 基于iii型纤连蛋白结构域的支架组合物、方法及用途 |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| EP2464663A4 (en) | 2009-08-13 | 2013-05-29 | Massachusetts Inst Technology | MANIPULATED PROTEINS WITH MUTANT FIBRONECTIN DOMAINS |
-
2008
- 2008-10-31 US US12/739,149 patent/US8633297B2/en active Active
- 2008-10-31 BR BRPI0818810-6A2A patent/BRPI0818810A2/pt not_active Application Discontinuation
- 2008-10-31 KR KR1020107011856A patent/KR101686247B1/ko active Active
- 2008-10-31 JP JP2010531076A patent/JP2011501951A/ja active Pending
- 2008-10-31 ES ES08845766.8T patent/ES2533874T3/es active Active
- 2008-10-31 AU AU2008319298A patent/AU2008319298B2/en active Active
- 2008-10-31 MX MX2010004374A patent/MX2010004374A/es active IP Right Grant
- 2008-10-31 EP EP08845766.8A patent/EP2215246B1/en active Active
- 2008-10-31 CA CA2704229A patent/CA2704229C/en active Active
- 2008-10-31 WO PCT/US2008/012398 patent/WO2009058379A2/en not_active Ceased
- 2008-10-31 CN CN2008801146605A patent/CN101932720A/zh active Pending
- 2008-10-31 RU RU2010121967/10A patent/RU2010121967A/ru not_active Application Discontinuation
-
2013
- 2013-12-13 US US14/106,689 patent/US9176129B2/en active Active
-
2014
- 2014-12-02 JP JP2014243591A patent/JP6034846B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501951A5 (OSRAM) | ||
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| AU2014301777B2 (en) | High-stability T-cell receptor and preparation method and application thereof | |
| JP6101638B2 (ja) | 多価ヘテロマルチマー足場設計及び構築物 | |
| CN103180339B (zh) | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 | |
| AU2017273743B2 (en) | Serum albumin-binding fibronectin type III domains | |
| JP2020511949A5 (OSRAM) | ||
| JP2016512213A5 (OSRAM) | ||
| JP2017527272A5 (OSRAM) | ||
| EA012507B1 (ru) | Высокоаффинные мелан-а т-клеточные рецепторы | |
| JP2013529070A5 (OSRAM) | ||
| RU2010121967A (ru) | Белковые каркасные структуры | |
| JP2017536098A5 (OSRAM) | ||
| JP2016516049A5 (OSRAM) | ||
| WO2009142773A4 (en) | Multivalent fibronectin based scaffold domain proteins | |
| DK2190863T3 (en) | New albumin binding compositions, methods and uses | |
| CA2863944A1 (en) | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds | |
| JP2015509707A5 (OSRAM) | ||
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| IL292358A (en) | specific binding molecules | |
| Lindgren et al. | A GLP‐1 receptor agonist conjugated to an albumin‐binding domain for extended half‐life | |
| WO2024084203A1 (en) | Single domain antibodies binding to albumin | |
| JP2019511457A5 (OSRAM) | ||
| CN115803339A (zh) | 特异性结合分子 | |
| CN107223133B (zh) | 一种可溶的异质二聚t细胞受体及其制法和应用 |